POS1147 FREQUENCY OF HUMAN PAPILLOMAVIRUS IN PATIENTS WITH MODERATE- SEVERE SYSTEMIC LUPUS ERYTHEMATOSUS
Authors: C. Lasa-Teja, C. Bejerano, V. Portilla González, A. Corrales Martinez, R. Blanco
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Human Papillomavirus (HPV) is associated to cervix cancer. Multiple sexual partners, oral contraceptives, smoking, or HIV infection are some of the main cofactors involved in its development. The overall risk of neoplasia is increased in patients with SLE, including cervix cancer. In SLE patients' additional factors may be also associated such as the immunosuppressive treatment (mainly Cyclophosphamide), the activity of the disease, and genetic factors. Cervix test is the best screening method for cervix precancerous lesions. <h3>Objectives:</h3> To assess the frequently of VPH in patients with moderate-severe systemic erythematosus lupus. <h3>Methods:</h3> Unicentric, observational and retrospective study of 86 patients with moderate-severe SLE diagnosis who have received treatment with Cyclophosphamide, Rituximab, Mycophenolate Mofetil and/or Belimumab in a University referral hospital in Northen Spain. Cytologies and HPV detection were collected according to regional clinical practice guidelines. Lesions were classified according to The Bethesda System as: Atypical Squamous Cells of Undetermined Significance" (ASC-US), low-grade SIL (LSIL), high-grade SIL (HSIL) and invasive squamous cell carcinoma. <h3>Results:</h3> We studied 86 patients, mainly female (n=74, 86.1%), of Caucasian race (n=81, 94.2%) with a median age 51 years and followed-up during a mean of 12.3±10.8 years from diagnosis (Table 1). Almost 54% of the patients have ever smoked. A positive Human Papillomavirus (HPV) were presented in 12 (13.9%) patients (11 women/1 man). A high-risk serotype was found in 9 (75%) of the patients. A total of 70 (94.6%) women had performed a cervical cytology. A positive one was found in 10 (14.3%) of patients (Table 2). One middle-aged women developed an epidermoid carcinoma of the uterine cervix IIIB with lymph node and pelvic involvement. This patient had received a cyclophosphamide treatment and had a type of high-risk HPV (Table 2). In addition, one man developed an anal intraepithelial neoplasia, and a high-risk HPV positive was found. <h3>Conclusion:</h3> Presence of HPV is relatively frequent in SLE. An exhaustive control in SLE patients could be necessary to achieve an early identification of precancerous/cancerous lesions through annual cytology. <h3>REFERENCES:</h3> [1] García-Carrasco M, Mendoza-Pinto C, Rojas-Villarraga A, Molano-González N, Vallejo-Ruiz V, Munguía-Realpozo P, Colombo AL, Cervera R. Prevalence of cervical HPV infection in women with systemic lupus erythematosus: A systematic review and meta-analysis. Autoimmun Rev. 2019 Feb;18(2):184-191. doi: 10.1016/j.autrev.2018.09.001. Epub 2018 Dec 18. Erratum in: Autoimmun Rev. 2019 Apr;18(4):437. PMID: 30572140. <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> Carmen Lasa-Teja: None declared, Carmen Bejerano: None declared, Virginia Portilla González: None declared, Alfonso Corrales Martinez: None declared, Ricardo Blanco AbbVie, MSD, and Roche., AbbVie, Pfizer, Roche, Bristol-Myers, Lilly, Galapagos, Novartis, Janssen, GSK, and MSD.